Background—Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy (HCM) and a
potential substrate for arrhythmias and heart failure. Sarcomere mutations seem to induce …

Background—Genetic testing identifies sarcomere mutation carriers (G+) before clinical
diagnosis of hypertrophic cardiomyopathy (HCM), allowing characterization of initial disease …

Purpose To evaluate myocardial strain and circumferential transmural strain difference
(cTSD; the difference between epicardial and endocardial circumferential strain) in a …

BACKGROUND: In hypertrophic cardiomyopathy (HCM), myocyte disarray and
microvascular disease (MVD) have been implicated in adverse events, and recent evidence …

Background—Left ventricular hypertrophy (LVH) typically manifests during or after
adolescence in sarcomere mutation carriers at risk for developing hypertrophic …

Aims In hypertrophic cardiomyopathy (HCM), attempts to associate genotype with phenotype
have largely been unsuccessful. More recently, cardiac magnetic resonance (CMR) imaging …

In hypertrophic cardiomyopathy (HC), electrocardiographic (ECG) changes have been
postulated to be an early marker of disease, detectable in sarcomere mutation carriers when …

Background Clinical data on myocardial function in HCM mutation carriers (carriers) is
sparse but suggests that subtle functional abnormalities can be measured with tissue …

Objectives: Our purpose was to characterize the pattern and distribution of left ventricular
(LV) hypertrophy by cardiovascular magnetic resonance (CMR) to more precisely define …

In hypertrophic cardiomyopathy (HCM), the clinical significance attributable to the broad
range of left ventricular (LV) systolic function, assessed as the ejection fraction (EF), is …